Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Return on Capital Employed (2022 - 2025)

Historic Return on Capital Employed for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to 0.34%.

  • Taysha Gene Therapies' Return on Capital Employed rose 2000.0% to 0.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.34%, marking a year-over-year increase of 2000.0%. This contributed to the annual value of 0.65% for FY2024, which is 100.0% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Return on Capital Employed of 0.34% as of Q3 2025, which was up 2000.0% from 0.45% recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Return on Capital Employed peaked at 2.64% during Q3 2023, and registered a low of 2.92% during Q2 2023.
  • Over the past 4 years, Taysha Gene Therapies' median Return on Capital Employed value was 0.59% (recorded in 2024), while the average stood at 0.81%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first skyrocketed by 24100bps in 2023, then tumbled by -31800bps in 2024.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Return on Capital Employed stood at 2.9% in 2022, then surged by 83bps to 0.49% in 2023, then dropped by -29bps to 0.63% in 2024, then soared by 46bps to 0.34% in 2025.
  • Its Return on Capital Employed was 0.34% in Q3 2025, compared to 0.45% in Q2 2025 and 0.7% in Q1 2025.